Health ProductsDear Healthcare Professional Letter

Sanis Quetiapine (quetiapine fumarate) - Voluntary Recall Due to Possible Contamination Issues - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Contamination
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Sanis Health Inc. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Sanis Quetiapine (quetiapine fumarate) tablets

May 17, 2013

Dear Health Care Professional,

Subject: Voluntary recall of Sanis Quetiapine (quetiapine fumarate) 25 mg (DIN 02353164), 100 mg (DIN 02353172), 200 mg (DIN 02353199) and 300 mg tablets (DIN 02353202) due to potential presence of trace amounts of Clindamycin hydrochloride in the tablets.

Sanis Health Inc., in consultation with Health Canada, is writing to advise you that the supplier of quetiapine fumarate active pharmaceutical ingredient (API) to Sanis Health Inc. may have inadvertently caused trace amounts of clindamycin hydrochloride to be present in the quetiapine raw material. Exposure to clindamycin, no matter how minor, may increase the risk of potentially serious allergic adverse drug reactions, in people taking Sanis Quetiapine tablets, particularly in those who are allergic or may also be sensitive to clindamycin hydrochloride or lincomycin hydrochloride. Quetiapine is an antipsychotic agent indicated for the management of schizophrenia and bipolar disorder in adult patients and is not indicated for use in patients who are under 18 years of age.  A voluntary recall has been initiated for Sanis Quetiapine products currently on the Canadian market and a list of the affected lot numbers is attached to this letter.

The population at risk is those who are susceptible or hypersensitive to clindamycin hydrochloride or lincomycin hydrochloride. The most common hypersensitivity reaction is generalized mild to moderate morbilliform-like (maculopapular) skin rashes. However, vesiculobullous rashes, urticaria, rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, and a few cases of anaphylactoid reactions have also been reported during drug therapy with clindamycin at recommended doses.

  • A voluntary recall of Sanis Quetiapine product has been initiated due to potential for trace amounts of clindamycin in affected quetiapine products and possible risk of serious allergic adverse reactions, particularly in those who are hypersensitive to clindamycin or lincomycin.
  • Health care professionals are advised to contact their patients who have been supplied with any Sanis Quetiapine product and ensure a safe transition over to an alternative quetiapine product which is not subject to recall or, to another product authorised for the Canadian market. Increased monitoring is recommended during the transition period.
  • Patients should not abruptly discontinue their treatment but contact their health care professional to obtain medical advice.

During a recent inspection by international inspectors from the European Directorate for the Quality of Medicines & HealthCare (EDQM), it was noted that the API manufacturer’s cleaning records for a piece of common equipment were found inadequate.  While there is no evidence indicating the Quetiapine fumarate product was in contact with clindamycin hydrochloride and, no allergic reaction adverse events have been reported to date, the presence of trace amounts of clindamycin hydrochloride on that common equipment has not yet been ruled out.  As a precaution, it is necessary to bring the possibility of a serious allergic reaction in patients sensitive to clindamycin hydrochloride to your attention.

For most adult patients, exposure to trace amounts of clindamycin hydrochloride will not represent a health risk. However, the data in the literature indicates a possibility of hypersensitivity in some patients. The prevalence of clindamycin hypersensitivity is expected to be less than 1%.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious allergic reaction or other serious or unexpected adverse reactions in patients receiving Sanis Quetiapine tablets should be reported to Sanis Health Inc. or Health Canada.

Sanis Health Inc.
333 Champlain St., Dieppe, NB
E1A 1P2
1-866-236-4076

To correct your mailing address or fax number, contact Sanis Health Inc.

You can also report any suspected adverse reactions associated with the use of health products to Health Canada by: 

  • Calling toll-free at 1-866-234-2345; or

For other health product inquiries related to this communication, contact Health Canada at:
Lead Directorate: Health Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636 

Please be assured that the health and safety of your patients is our primary concern.  

Sincerely,

Original signed by

Paul Bonnici
Director, Regulatory Affairs

References:

  1. Sanis Quetiapine (Quetiapine fumarate) Tablets, Product Monograph, revised May 10, 2012.
  2. DALACIN C, (Clindamycin Hydrochloride Capsules USP) Product Monograph, revised November.
  3. DALACIN C, (Clindamycin Hydrochloride Capsules USP) Product Monograph, revised November 8, 2012
  4. US Prescribing Information. Clindamycin Hydrochloride Capsules. Actavis, Inc. September 2012. 
  5. Mazur N, Greenberger PA, Regalado J. Clindamycin hypersensitivity appears to be rare. Ann Allergy Asthma Immunol. May 1999;82(5):443-5
Lots Affected by recall
Product Lot #
Sanis Quetiapine 25 mg Tablets 100's CK261
Sanis Quetiapine 25 mg Tablets 500's CK262
Sanis Quetiapine 300 mg Tablets 500's CJ724
Sanis Quetiapine 100 mg Tablets 100's CK28B
Sanis Quetiapine 100 mg Tablets 500's CK29A
Sanis Quetiapine 300 mg Tablets 100's CM812
Sanis Quetiapine 100 mg Tablets 500's CM771
Sanis Quetiapine 200 mg Tablets 500's CM792
Sanis Quetiapine 200 mg Tablets 100's CM793
Sanis Quetiapine 25 mg Tablets 100's CM682
Sanis Quetiapine 25 mg Tablets 500's CM691
Sanis Quetiapine 25 mg Tablets 100's CP922
Sanis Quetiapine 25 mg Tablets 500's CT122
Sanis Quetiapine 25 mg Tablets 500's CP961
Sanis Quetiapine 100 mg Tablets 100's CU141
Sanis Quetiapine 100 mg Tablets 500's CU142
Sanis Quetiapine 25 mg Tablets 100's CP91B
Sanis Quetiapine 200 mg Tablets 100's CU572
Sanis Quetiapine 25 mg Tablets 500's CW362
Sanis Quetiapine 300 mg Tablets 100's CW303
Sanis Quetiapine 100 mg Tablets 100's CW351
Sanis Quetiapine 100 mg Tablets 500's CW352
Sanis Quetiapine 25 mg Tablets 500's   DB971
Sanis Quetiapine 200 mg Tablets 100's CZ771
Sanis Quetiapine 200 mg Tablets 500's CZ773
Sanis Quetiapine 25 mg Tablets 500's DC161
Sanis Quetiapine 100 mg Tablets 100's DC192
Sanis Quetiapine 300 mg Tablets 100's CZ783
Sanis Quetiapine 200 mg Tablets 100's DD721
Sanis Quetiapine 300 mg Tablets 100's DD961
Sanis Quetiapine 300 mg Tablets 100's DD981
Sanis Quetiapine 25 mg Tablets 500's DG162
Sanis Quetiapine 25 mg Tablets 500's DG182
Sanis Quetiapine 200 mg Tablets 500's DG023
Sanis Quetiapine 200 mg Tablets 100's DG021
Sanis Quetiapine 25 mg Tablets 100's DG181
Sanis Quetiapine 100 mg Tablets 100's DG191
Sanis Quetiapine 100 mg Tablets 500's DG211
Sanis Quetiapine 300 mg Tablets 100's CJ724D1
Sanis Quetiapine 25 mg Tablets 500's DK941
Sanis Quetiapine 100 mg Tablets 100's DK95A
Sanis Quetiapine 200 mg Tablets 100's DG02DA
Sanis Quetiapine 200 mg Tablets 100's DT05A
Sanis Quetiapine 100 mg Tablets 100's DK95ADA
Sanis Quetiapine 25 mg Tablets 500's DS99A
Sanis Quetiapine 25 mg Tablets 100's DS95B
Sanis Quetiapine 100 mg Tablets 500's DT04A
Sanis Quetiapine 300 mg Tablets 100's DT07A

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime